| Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 18932051 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: A prior report suggested that individuals medicated with captopril showed a decreased incidence of prostate cancer. This study therefore investigated whether captopril given postoperatively had any preventive effect on biochemical recurrence for patients treated with radical prostatectomy. MATERIAL AND METHODS: Data were prospectively reviewed for 62 men subjected to radical retropubic prostatectomy due to biopsy-confirmed, clinically localized prostate cancer and comparisons were made between two groups, those receiving captopril postoperatively (12.5 mg twice daily; captopril group, n=32) and those not receiving any captopril (control group, n=30). One surgeon carried out the surgery. RESULTS: The two groups were comparable as regards age at surgery, prostate volume, preoperative prostate-specific antigen values, pathological stage, Gleason score, organ-confined disease, occurrence of positive surgical margins and extraprostatic extension. The incidence of biochemical failure was three out of 32 patients in the captopril group and 10 out of 30 in the control group (p=0.034) during a mean observational time of 29 months. CONCLUSIONS: A lower rate of biochemical recurrence was observed in men subjected to radical prostatectomy treated with captopril postoperatively than in those not receiving captopril. These results were based on only 32 observations; a larger study may show no evidence of an association. |
| | |
Authors:
|
Gunnar Ronquist; Goran Frithz; Yu-Hui Wang; Torsten Lindeborg |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Scandinavian journal of urology and nephrology Volume: 43 ISSN: 0036-5599 ISO Abbreviation: Scand. J. Urol. Nephrol. Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-01-20 Completed Date: 2009-03-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0114501 Medline TA: Scand J Urol Nephrol Country: Sweden |
Other Details:
|
Languages: eng Pagination: 32-6 Citation Subset: IM |
Affiliation:
|
Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden. gunnar.ronquist@akademiska.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Captopril / therapeutic use* Humans Male Middle Aged Neoplasm Invasiveness Neoplasm Recurrence, Local / prevention & control* Postoperative Period Prostate-Specific Antigen / blood* Prostatectomy* Prostatic Neoplasms / pathology, surgery* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 62571-86-2/Captopril; EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phenotypic variance in childhood coeliac disease and the HLA-DQ/DR dose effect.
Next Document: Intention and attention in ideomotor learning.